MEDI-522

BIOLOGICAL6 trials

Sponsors

MedImmune LLC

Conditions

CancerMalignant MelanomaProstate CancerPsoriasisRheumatoid Arthritis

Phase 1

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

CompletedNCT00111696

MedImmune LLCMalignant Melanoma

Start: 2005-05-31End: 2007-11-30Updated: 2012-03-14

Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors

CompletedNCT00263783

MedImmune LLCCancer

Start: 2001-03-31End: 2002-06-30Target: 24Updated: 2009-01-29

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

CompletedNCT00284817

MedImmune LLCCancer

Start: 2001-07-31End: 2005-05-31Updated: 2008-05-29

Phase 2

Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate

CompletedNCT00069017

MedImmune LLCRheumatoid Arthritis

Start: 2003-09-30End: 2006-04-30Updated: 2007-11-27

MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

CompletedNCT00072930

MedImmune LLCProstate Cancer

Start: 2003-12-31End: 2007-06-30Target: 150Updated: 2008-01-15

Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

CompletedNCT00192517

MedImmune LLCPsoriasis

Start: 2003-12-31End: 2004-09-30Updated: 2009-04-03